✓ Translated by DotMD AI Clinical Council Source: Frontiers in endocrinology • Randomized Controlled Trial
Verify Primary Source: NIH PubMed PMID #32499757 ↗

Randomized Controlled Trial: Aromatase Inhibitors Plus Weight Loss Improves the Hormonal Profile of Obese Hypogonadal Men Without Causing Major Side Effects (N = 12)

Original Paper Title: “Aromatase Inhibitors Plus Weight Loss Improves the Hormonal Profile of Obese Hypogonadal Men Without Causing Major Side Effects”

Elena Rostova (AI Quant) Rigor Score
88 / 100
Sample Size (Participants)
N = 12
Evidence Classification
Randomized Controlled Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • Conclusions: Although AI+WL is effective in reversing the hormonal profile of HHG in severely obese men without causing major side effects, it does not lead to greater improvements in muscle strength and symptoms of hypogonadism compared to WL alone. Clinical Trial Registration : www.ClinicalTrials.gov, identifier: NCT02959853.
  • Study Design & Sample: Randomized Controlled Trial published in Frontiers in endocrinology (N = 12 human participants).
  • Biostatistical Rigor Score: 88/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Frontiers in endocrinology (2020), this randomized controlled trial evaluating 12 human participants investigated: Objective: In obese men, the increased expression of the aromatase enzyme in adipose tissue leads to high conversion of androgens to estrogens contributing to hypogonadotropic hypogonadism (HHG). Key clinical takeaway: Conclusions: Although AI+WL is effective in reversing the hormonal profile of HHG in severely obese men without causing major side effects, it does not lead to greater improvements in muscle strength and symptoms of hypogonadism compared to WL alone. Clinical Trial Registration : www.ClinicalTrials.gov, identifier: NCT02959853.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Frontiers in endocrinology, 2020-01-15; N = 12; Rigor 88/100): Conclusions: Although AI+WL is effective in reversing the hormonal profile of HHG in severely obese men without causing major side effects, it does not lead to greater improvements in muscle strength and symptoms of hypogonadism compared to WL alone. Clinical Trial Registration : www.ClinicalTrials.gov, identifier: NCT02959853.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Randomized Controlled Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: estradiol-vaginal-cream → Rx: estradiol → Rx: zinc-cold-therapy-zinc-gluconate → Rx: ultra-zinc-cold-therapy-zincum-gluconicum → Condition: malnutrition → Condition: metabolic-syndrome →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 32499757: Randomized Controlled Trial: Aromatase Inhibitors Plus Weight Loss Improves the Hormonal Profile of Obese Hypogonadal Men Without Causing Major Side Effects (N = 12)

3 of 3 Free Questions Remaining